Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials

International Journal of Oncology

Volumn 36, Issue 3, 2010, Pages 601-606

  Jatoi, Aminah ^a   Foster, Nathan R ^a   Egner, James R ^b   Burch, Patrick A ^a   Stella, Philip J ^c   Rubin, Joseph ^a   Dakhil, Shaker R ^d   Sargent, Daniel J ^a   Murphy, Brian R ^e   Alberts, Steven R ^a  

^a MAYO CLINIC ROCHESTER   (United States)

^b Carle Cancer Center CCOP   (United States)

^c Michigan Cancer Research Consortium   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e Toledo Community Hospital Oncology Program CCOP   (United States)

Author keywords

Adverse events; Chemotherapy; Elderly; Esophageal cancer

Indexed keywords

BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIA CARCINOMA; DIARRHEA; DYSPNEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HUMAN; HYPOTENSION; INFECTION; KIDNEY FAILURE; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; ADENOCARCINOMA; AGE; CLINICAL TRIAL (TOPIC); ESOPHAGEAL NEOPLASMS; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; PATHOLOGY; STOMACH NEOPLASMS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NORTH CAROLINA; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77149172847     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000535     Document Type: Article

References (26)

1. Blank TO and Bellizzi KM: A gerontologic perspective on cancer and aging. Cancer 112 (Suppl): 2569-2576, 2008.
2. El-Serag HB: The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am 31: 421-440, 2002.
3. Morita M, Egashira A, Yoshida R, et al: Esophagectomy in patients 80 years of age and older with carcinoma of the thoracic esophagus. J Gastroenterol 43: 345-351, 2008.
4. Internullo E, Moons J, Nafteux P, et al: Outcome after esophagectomy for cancer of the esophagus and GEJ in patients aged over 75 years. Eur J Cardiothorac Surg 33: 1096-1104, 2008.
5. Takeuchi S, Ohtsu A, Doi T, et al: A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol 30: 607-611, 2007.
6. Ruol A, Portale G, Castoro C, et al: Effects of neoadjuvant therapy on perioperative morbidity in elderly patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol 14: 3243-3250, 2007.
7. Ruol A, Portale G, Castoro C, et al: Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg 32: 445-448, 2007.
8. Kim JH, Chung HS, Youn YH, et al: Treatment outcomes of 70 cases of early esophageal carcinoma: 12 years of experience. Dis Esophagus 20: 297-300, 2007.
9. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D and Ilson DH: Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 96: 1823-1827, 2007.
10. Wheatley-Price P, Ding K, Seymour L, Clark GM and Shepherd FA: Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 2350-2357, 2008.
11. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097, 2001.
12. Muss HB, Berry DA, Cirrincione C, et al: Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25: 3699-3704, 2007.
13. Lipscombe LL, Gomes T, Levesque LE, et al: Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298: 2634-2643, 2007.
14. Hsu J, Fung V, Price M, et al: Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA 299: 1929-1936, 2008.
15. Al-Batram SE, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkolgie. J Clin Oncol 26: 1435-1442, 2008.
16. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
17. MacDonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
18. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3205-3209, 2007.
19. Elliott TE, Moertel CG, Wieand HS, et al: A phase II study of the combinatin of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer 65: 1491-1494, 1990.
20. Rubin J, Gallagher JG, Schroeder G, et al: Phase II trials of f-fluorouracil and leucovorin in patients with metastatic gastric or pancreas carcinoma. Cancer 78: 1888-1891, 1996.
21. Burch PA, Keppen MD, Schroeder G, et al: North Central Cancer Treatment Group phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary end-point of efficacy. Am J Clin Oncol 22: 505-508, 1999.
22. Erlichman C, Goldberg RM, Mahoney MR, et al: A phase II trial of CPT-11 in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group Study 23: S16, 4026A, 2005.
23. Jatoi A, Tirona MT, Cha SS, et al: A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 32: 115-123, 2002.
24. Jatoi A, Murphy BR, Foster NR, et al: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17: 29-34, 2006.
25. Giordano KF, Jatoi A, Stella PF, et al: Docetaxel and capecitabine in patients with metastatic adenocarcinoma for the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17: 652-656, 2006.
26. Jatoi A, Dakhil SR, Foster NR, et al: Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesopheal cancer: phase II results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 3: 516-520, 2008.